Ditropan Articles
J&J's Ditropan to get stronger warnings
16 April 2007
Appeals court rules for Mylan on oxybutynin
18 September 2006
Tentative FDA OK for IMPAX generic Ditropan
7 February 2005
Tenetative US appro for Mylan's oxybutynin
24 January 2005
Indevus files for OAB drug trospium in USA
5 May 2003
Watson's incontinence patch cleared by US FDA
3 March 2003
Urinary incontinence market forecasts
10 August 2001
CORRECTION: Uros
9 August 2001
Alza to market Ditropan in Canada
14 June 2001
Ditropan XL vs Detrol study in incontinence
11 April 2001
Alza Corp acquires marketing rights to Flexeril from Merck & Co
6 February 2001
Alza Corp revenues pushing $1 billion
1 February 2001
Stock Commentary New York
29 June 2000
Sanofi-Synthelabo gains UK approval for Ditropan XL
20 June 2000
Alza revenues top $200 million mark
20 April 2000
J&J ends Alza JV for E-TRANS - update
23 February 2000
J&J ends Alza JV for E-TRANS
18 February 2000
Busy year for NCEs as major new compound classes launched
6 January 2000
Sanofi-Synthelabo's once-daily Ditropan filed in UK
12 August 1999
Alza Corp to push Ditropan sales
23 July 1999
Alza's Ditropan XL Reduces Urinary Incontinence
17 June 1999
Alza's Ditropan XL vs immediate-release form
28 May 1999
Stock Commentary New York
8 April 1999
Stock Commentary New York
31 March 1999
Alza's Ditropan XL cleared by FDA- updated story
7 January 1999
Alza's Ditropan cleared by FDA
21 December 1998
Analysts Taking Stock Of Pharma Firms, Prospects Still Good
26 November 1998
Alza Boosts Ditropan XL Sales Effort
24 August 1998
Generic Ditropan From Morton
19 March 1997
Sepracor Incontinence Drug Cleared For Trials
9 December 1996
Smith & Nephew Sells Incontinence Medicine To Synthelabo
4 December 1995
Fournier Forces Job Cuts At Debat
9 January 1995
SMITH & NEPHEW GAINS INJUNCTION
21 February 1994
ANANXYL WITHDRAWN FROM MARKET IN FRANCE
1 November 1993
SYNTHELABO EXPECTS 23% RISE IN '93 PROFITS
25 October 1993
ABPI SEES 14 BREACHES OF PRACTICE CODE
12 April 1993
ABPI CODE OF PRACTICE LATEST REPORT
21 December 1992
Showing 1-44 of 44 articles
- 1
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
